Autologous Immune Enhancement Therapy (AIET) for Cancer Patients

Vinmec Research Institute of Stem Cell and Gene Technology

Status and phase: Completed; Phase 1

Conditions: Patients With Cancer

Treatments: Combination Product: Autologous immune enhancement therapy (AIET) for cancer patients

Study type: Interventional

Funder types: Other

Identifiers

NCT05520372

AIET_2022

Details and patient eligibility

About

This is a retrospective study that included 60 cancer patients who underwent autologous NK cell and CD8 T cell therapy between January 2016 and December 2021

Full description

The dysfunction and reduced proliferation of peripheral immune cells including CD8 T and NK cells have been observed in both aging and cancer patients, thereby challenging the immune cell therapy in these subjects. Therefore, we evaluated the growth of these lymphocytes in elderly patients with several types of cancer and the correlation of peripheral blood (PB) indexes to the expansions. This is a retrospective study that included 60 cancer patients who underwent autologous NK cell and CD8 T cell therapy between January 2016 and December 2021. By optimizing the antiviral and tumor surveillance ability of both NK cells and CTLs through serial steps from isolation and expansion, followed by re-infusion of these activated cells back to the patient body, AIET has become a promising, cutting-edge method in detecting and eliminating cancer cells. The study aimed to evaluate the safety and effectiveness of 60 cancer patientsreceiving AIET.

Enrollment: 60 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged 18 - 75
• Patients have been diagnosed with cancer.
• Patients signed the written informed consent form.

Exclusion criteria

• Severe health conditions such as serious infection, autoimmune diseases, or using any anti-rejection drugs

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

60 participants in 1 patient group

autologous immune enhancement therapy (AIET) for treating cancer

Experimental group

Description:

A total of 60 cancer patients received one to seven sittings of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) infusions.

Treatment:

Combination Product: Autologous immune enhancement therapy (AIET) for cancer patients